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ABSTRACT
Implantable cardioverter defibrillator (ICD) implantation
carries a significant risk of complications, however
published estimates appear inconsistent. We aimed to
present a contemporary systematic review using meta-
analysis methods of ICD complications in randomised
controlled trials (RCTs) and compare it to recent data
from the largest international ICD registry, the US
National Cardiovascular Data Registry (NCDR).
PubMed was searched for any RCTs involving ICD
implantation published 1999–2013; 18 were identified for
analysis including 6433 patients, mean follow-up
3m o n t h s –5.6 years. Exclusion criteria were studies of
children, hypertrophic cardiomyopathy, congenital heart
disease, resynchronisation therapy and generator
changes.
Total pooled complication rate from the RCTs
(excluding inappropriate shocks) was 9.1%, including
displacement 3.1%, pneumothorax 1.1% and
haematoma 1.2%. Infection rate was 1.5%.There were no
predictors of complications but longer follow-up showed
a trend to higher complication rates (p=0.07). In
contrast, data from the NCDR ICD, reporting on 356 515
implants (2006–2010) showed a statistically significant
threefold lower total major complication rate of 3.08%
with lead displacement 1.02%, haematoma 0.86% and
pneumothorax 0.44%.
The overall ICD complication rate in our meta-analysis
is 9.1% over 16 months. The ICD complication reported
in the NCDR ICD registry is significantly lower despite a
similar population. This may reflect under-reporting of
complications in registries. Reporting of ICD
complications in RCTs and registries is very variable and
there is a need to standardise classification of
complications internationally.
INTRODUCTION
The implantable cardioverter deﬁbrillator
(ICD) is a now established treatment for many
individuals considered to be at an increased
risk of sudden cardiac death.
1 The survival
beneﬁt appears to be comparable between
clinical trial patients and those observed in
real world practice.
2 However, ICD implant-
ation inevitably carries a risk of complications.
Implanters rely on locally available data as well
as that reported in the international literature
to inform patients of the risks involved. This
information may be particularly important
when considering implantation for a border-
line indication. When benchmarking their
practice, institutions may base their targets on
ﬁgures derived from published data, utilising
complementary resources such as registries
and randomised clinical trials (RCTs).
However, there is a paucity of consistent data
on the complication rates of ICD implantation
in the modern era. The most recent systematic
review of the evidence from RCTs
3 was a
mixed study of both ICD and cardiac resyn-
chronisation therapy (CRT) devices with series
dating back to 1996, including a number of
devices implanted by thoracotomy and the
incidence of infection was not reported.
Although registry data are available, it is not
clear how these compare to that compiled
from RCTs. Despite this, registry data have
recently been utilised to develop a risk model
for adverse events during ICD implantation.
4
Therefore, this study aimed to compare the
complication rates reported in RCTs with the
so-called ‘real-world’ experience observed in
registries and to examine the quality of compli-
cation reporting in the literature in order to
assess whether registry data really can be uti-
lised to reﬂect current real-world experience.
The study assessed the risk of complications
from contemporary ICD implantation by a
pooling of results from RCTs using meta-ana-
lysis methods and compared this data to the
largest ICD registry to date.
5
METHODS
Literature review, inclusion and exclusion
criteria
PubMed was searched on 31 July 2013 for
English language RCTs in humans, with
abstracts available, using the following criteria:
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Arrhythmias and sudden death(implantable cardioverter deﬁbrillator OR ICD) AND
(complications OR adverse event) NOT ICD-9 NOT
ICD-10. This identiﬁed 187 articles which were screened
and of these, 17 met the criteria for inclusion, which were
any RCT reporting explicit data on transvenous, non-
thoracotomy ICD complications (except inappropriate
ICD intervention) regardless of whether or not the study
was primarily of ICDs. In the case of serial publications,
only the most recent or most appropriate study was
included in the analysis. Exclusion criteria were studies
speciﬁcally of hypertrophic cardiomyopathy (HCM), chil-
dren, congenital heart disease, resynchronisation therapy
and generator changes. Complications of ICD implant-
ation occurring in patients with HCM have recently been
comprehensively presented in a review by Schinkel et al
6
The IRIS study
7 (which was not returned in the original
search due to use of the MESH term ‘adverse effects’
rather than ‘adverse events’) was also subsequently
included in the analysis, thus bringing the total number of
RCTs to 18.
Data extraction
Selected RCTs were reviewed and relevant patient
characteristics, potential risk factors for complications
and follow-up duration were recorded. No time restric-
tion for complications was used. Even after exclusion of
studies without explicit complication data, the studies
varied greatly in the manner and depth in which compli-
cations were reported and not all described a detailed
breakdown. The outcome data available therefore varied
according to the criteria used in each particular RCT.
An inclusive list of the different complication categories
used by the studies is as follows: total complications,
30-day mortality, pneumothorax, haemothorax, haema-
toma, bleeding, dissection, perforation, tamponade,
need for transfusion, thrombosis, displacement, displace-
ment requiring repositioning, other displacement, lead
failure or dislodgement, need for lead revision/replace-
ment, need for additional lead, lead fracture, insulation
failure, lead under sensing, T wave over sense, generator
failure, generator migration/erosion, generator revision,
infection, erosion and Twiddler’s syndrome.
Statistical analysis
Statistical analysis was performed using Microsoft Excel
2010 (Microsoft Corporation, Redmond, Washington,
USA) and COMPREHENSIVE META-ANALYSIS software
V.2, Biostat, Englewood, USA. Complication event rates
were pooled together using inverse variance weighting.
Heterogeneity among the studies was evaluated using the
I
2index. Publication bias was assessed by Begg’s adjusted
rank correlation test and Egger’s regression asymmetry test.
Continuous variables were reported as mean. Categorical
v a r i a b l e sw e r es u m m a r i s e da sp e r c e n t a g e s .F r o mt h e
pooled data, a ﬁxed effects model was used to calculate
summary estimates of patient characteristics and potential
risk factors for complications. Meta regression analysis was
used to investigate if any variable was associated with
speciﬁc study outcomes. Poisson regression was used to
comparing data from RCTs to that from the registry.
RESULTS
Included studies
The literature search yielded 187 articles. The abstracts
or full text of these were reviewed and a total of 17
included in the systematic review with one further study
added later.
7 Baseline characteristics are shown in table 1.
A total of 6796 patients were included in the analysis. All
were non-thoracotomy systems. Year of publication
ranged from 2001 to 2011. Average mean follow-up
period was 17.9 months.
Complications
A total of 532 patients (pooled event rate 9.1%) had an
ICD-related complication. All complications were consid-
ered to be major in that they required intervention or
further hospitalisation. The authors chose to classify com-
plications where possible into the following categories:
1. Access-related: This refers to any complication that was
vessel-related or occurred while gaining access to the
vasculature or the device pocket. This includes
pneumothorax, haemothorax, haematoma (including
need for transfusion) and thrombosis.
2. Lead-related: Lead-related refers to any complication
caused by placement of the lead or subsequently related
directly to the lead, for example, dissection or perfor-
ation (to include tamponade), displacement, fracture,
undersensing or oversensing, insulation defects and the
need for any lead revision regardless of cause.
3. Generator-related: This includes generator failure and
any need for generator revision, for example, migra-
tion or erosion but excluding infection which was
classiﬁed separately.
4. Infection: This included (where speciﬁed) infection
requiring intervention, including the use of antibiotic
therapy or device extraction.
Complication rates of the aforementioned categories
are shown in table 2 including the most uniformly
reported individual complications—pneumothorax,
haematoma and lead displacement.
On meta regression the only variable showing a rela-
tionship with complication rate was length of follow-up
which was of borderline statistical signiﬁcance (p=0.07).
A 6-month increase in follow-up time was associated with
a 15% increase in complication rate (95% CI −2% to
34% increase). There was no evidence that year of publi-
cation, age, gender, presence or absence of diabetes or
ischaemic heart disease or ejection fraction (EF) were
associated with rates of complications.
Mortality: In-hospital and 30 day mortality were not con-
sistently reported in the trials, although some speciﬁed
that there were no ‘implant-related deaths’. Given the
high-risk nature of many patients receiving ICDs, it may be
difﬁcult to ascertain the extent to which an ICD implant
per se has contributed to any subsequent early death. Of
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Open Heartthe six 30-day deaths occurring in the AVID study,
8 two
were potentially related to device implantation.
Registry data
The largest registry population of ICD patients is the US
National Cardiovascular Data Registry (NCDR) ICD regis-
try. A report speciﬁcally looking at the relationship
between physician procedure volume and ICD complica-
tion published in 2012,
5 included 356 515 initial ICD
implantations performed between 2006 and 2010. This
study was chosen as the most contemporaneous registry
to our RCT meta-analysis population and was comparable
also in age, gender and left ventricular (LV) function
(73% male, mean age 67.3 years and mean EF 28%). For
this registry population, the total in-hospital complication
rate (deﬁned as cardiac arrest, cardiac perforation, valve
injury, coronary venous dissection, haemothorax,
pneumothorax, deep vein thrombosis, transient ischae-
mic attack, stroke, myocardial infarction, pericardial tam-
ponade, arteriovenous ﬁstula, drug reaction, conduction
block, haematoma, lead dislodgement, peripheral
embolus, superﬁcial phlebitis, peripheral nerve injury
and device-related infection) was 3.08%; lead displace-
ment was 1.02%, haematoma 0.86% and pneumothorax
0.44%. Infection rate was not separately reported. A com-
parison of the complication rates reported in our review
and from the registry data is shown in ﬁgure 1.
Complication rates reported in the RCTs were signiﬁ-
cantly higher than those reported in the registry.
A more recent publication covering the periods
quarter 2 to quarter 4 of 2010 and all 4 quarters of
2011, including 263 284 procedures performed in
259 395 patients (including children), reported a total
adverse event rate of 2.16%, that is, lower than that
reported in the previous 5 years (as might be expected
with increased experience); specifying haematoma
requiring treatment at 0.34%, infection 1.49%, perpro-
cedural dislodgement 2.84%, perforation 0.16% and
pericardial tamponade 0.12%.
9
Infection
Infection occurred in 1.5% of RCTs cases included in
this review. All but three of the 10 studies reporting
infection rates deﬁned infection as requiring removal of
the device, although chronology was not speciﬁed. The
AVID study deﬁned device infection as requiring hospi-
talisation or prolongation of hospitalisation (if already
hospitalised) with administration of intravenous antibio-
tics with or without explantation.
8 The DATAS study did
not specify whether or not intervention was required but
reported only ‘pocket infections’,
10 while the DEFINITE
study also did not specify if intervention were required
but reported only one ‘infection’.
11 Incidence of infec-
tion was not described in the NCDR ICD registry publi-
cation from 2012, nor in the most recent previous
meta-analysis,
3 however it was almost identical in the
most recent NCDR ICD registry data (1.49%).
9
DISCUSSION
This systematic review of ICD implantation in almost
6800 patients with ischaemic heart disease and dilated
Table 1 Baseline characteristics of the included studies
Trial Year N
Mean
Follow-up
(months)
Mean
age
(years)
Per cent
male
Mean
EF (%)
Per cent
IHD
Per cent
DM
1 Calkins et al
23 SCV vs cephalic
approach
2001 71 18 65 61 42 NA NA
2 Deisenhofer et al
24 Dual vs single
chamber
2001 92 8 61 90 NA 67 NA
3K r o n et al
8 AVID 2001 539 27 65 79 32 81 26
4 Bänsch et al
25 CAT 2002 50 66 52 86 24 0 NA
5 Moss et al
26 MADIT 2002 742 20 64 84 23 100 33
6 Vollman et al
27 6944 vs 6942 2003 542 11 65 83 34 72 NA
7 Bänsch et al
28 1+1 2004 102 12 NA NA 38 82 NA
8 Bokhari et al
29 CIDS subset 2004 60 67 64 83 34 80 12
9 Hohnloser et al
30 DINAMIT 2004 310 30 62 81 28 100 31
10 Kadish et al
11 DEFINITE 2004 229 29 58 72 21 0 23
11 Bänsch et al
31 Quick-ICD 2007 190 12 63 86 41 64 NA
12 Reddy et al
32 SMASH-VT 2007 128 22 67 87 32 100 44
13 Almendral et al
10 DATAS 2008 334 15 64 84 36 85 24
14 Russo et al
33 INTRINSIC RV 2009 1530 11 65 81 NA 58 27
15 Steinbeck et al
7 IRIS 2009 415 37 63 83 35 77 37
16 Kuck et al
34 VTACH 2010 107 23 66 93 34 100 NA
17 Varma et al
35 TRUST 2010 1339 11 64 72 29 67 NA
18 Cheng et al
36 Warfarin 2011 16 1 71 79 37 49 23
Summary estimate 6796 17.9 64 80 30.5 74.0 29.1
DM, diabetes mellitus; IHD, ischaemic heart disease; NA, not available.
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Access-related, n (%) Lead-related, n (%)
Generator-related,
n (%)
Infection,
n (%)
Patients,
n
All events,
n (%) Total Pneumothorax Haematoma Total Displacement
Calkins et al
23 71 2 (2.8) 1 (1.4) – 1 (1.4) 1 (1.4) 1 (1.4) – 0
Deisenhofer et al
24 92 10 (10.9) 2 (2.2) 1 (1.1) 1 (1.1) 8 (8.7) –– 0
Kron et al
8 539 68 (12.6) 16 (3.0) 6 (1.1) 8 (1.5) 31 (5.8) 11 (2.0) 7 (1.3) 14 (2.6)
Bänsch et al
25 50 14 (28) 2 (4.0) – 2 (4.0) 10 (20.0) 9 (18) – 2 (4.0)
Moss et al
26 742 18 (2.4) –– – 13 (1.8) –– 5 (0.7)
Vollman et al
27 542 64 (11.8) –– – 45 (8.3) 8 (1.5) ––
Bänsch et al
28 102 20 (19.6) –– – 20 (19.6) 9 (8.8) ––
Bokhari et al
29 60 21 (35) –– – 18 (30) 2 (3.3) – 3 (5.0)
Hohnloser et al
30 310 25 (8.1) –– – 7 (2.3) –– –
Kadish et al
11 229 13 (5.7) 5 (2.2) 1 (0.4) –– – – 1 (0.4)
Bänsch et al
31 190 3 (1.6) 1 (0.5) – 1 (0.5) 2 (1.1) 1 (0.5) ––
Reddy et al
32 128 0 –– – –– – 0
Almendral et al
10 334 30 (9.0) 11 (3.3) 4 (1.2) 4 (1.2) 15 (4.5) 13 (3.9) – 4 (1.2)
Russo et al
33 1530 71 (4.6) 15 (1.0) – 15 (1.0) 33 (2.2) 23 (1.5) 38 (2.5) –
Steinbeck et al
7 415 76 (18.3) –– – –– – –
Kuck et al
34 107 15 (14.0) –– – 6 (5.6) 4 (3.7) 7 (6.5) 1 (0.9)
Varma et al
35 1339 81 (6.0) –– – –– – –
Cheng et al
36 16 1 (6.3) –– – –– – –
Event rate, %
(95% CI)
9.1
(6.4 to
12.6)
2.1
(1.3 to
3.3)
1.1
(0.6 to 1.8)
1.2
(0.9 to 1.7)
5.8
(3.3 to
9.8)
3.1
(1.7 to 5.8)
2.7
(1.3 to 5.7)
1.5
(0.8 to
2.6)
4
E
z
z
a
t
V
A
,
L
e
e
V
,
A
h
s
a
n
S
,
e
t
a
l
.
O
p
e
n
H
e
a
r
t
2
0
1
5
;
2
:
e
0
0
0
1
9
8
.
d
o
i
:
1
0
.
1
1
3
6
/
o
p
e
n
h
r
t
-
2
0
1
4
-
0
0
0
1
9
8
O
p
e
n
H
e
a
r
tcardiomyopathy enrolled in RCTs, found an overall com-
plication rate of 9.1%, the majority of which arose from
early complications of access issues or lead displacement
(5.2%). This is almost threefold higher than that
reported in the NCDR registry publication and import-
antly may also be more than that often quoted by physi-
cians to patients when considering ICD implantation.
Similarly, individual complications of lead displacement,
haematoma and pneumothorax were also all higher
than those reported by the registry. The only complica-
tion rate reported which was comparable between the
RCT and registry population in the more recent publica-
tion, was infection at 1.5%. A higher event rate in RCTs
would not necessarily be expected since many trials may
exclude the most high-risk patients and theoretically
might therefore represent a less frail population than
that of a registry. In addition, patients enrolled in RCTs
may potentially be treated by the more experienced
operators of a centre while procedures in registry
patients might conceivably be performed by operators
with a wider range of experience.
There are a number of possible explanations for these
ﬁndings. There was a wide variation in complication
rates observed in the RCTs with the highest rates mainly
reported from 2002–2004, reﬂecting the experience and
developments of the late 1990s. Given the slightly more
contemporary nature of the registry data it is possible
that the lower complication rate reﬂects increased oper-
ator experience and improved device/lead technology.
This seems unlikely to be a complete explanation
however, given that a number of the larger RCTs (there-
fore contributing more signiﬁcantly statistically to the
pooled data) included in our review were published in
the late 2000s. The relationship between complication
rate and length of follow-up, which on meta-regression
was of borderline statistical signiﬁcance (p=0.07), may
however be of particular relevance in this context. The
follow-up period reported in this meta-analysis was dic-
tated by the data available from the RCTs and was not
speciﬁcally restricted to either acute or late-presenting
complications. It is obviously important to recognise that
in contrast, the NCDR data reports speciﬁcally on
in-hospital complications only. Nevertheless, the fact that
early complications of lead displacement, haematoma
and pneumothorax rates (all of which present either
in-hospital or at early follow-up) were also all higher
than in the RCTs than in the registry, indicates that
length of follow-up is unlikely to account for these differ-
ences between RCTand registry data.
A further reason is that there is signiﬁcant under-
reporting of complications in some registry data. From
the NCDR ICD registry data in 2010,
12 the mean compli-
cation rate for all new ICD implants (2006–2009) was
3.22%, however the median event rate, which may be a
more meaningful representation, was 7% with the
highest decile 13%. Interestingly, the Ontario ICD regis-
try of over 3000 patients recorded an overall complica-
tion rate of 8.5% but made a distinction between major
and minor complications,
13 reporting a major complica-
tion rate of 4.1%. Minor complications included sub-
clavian vein thrombosis and pocket haematoma which
may be considered contentious, for example, given the
possible association between haematoma and infec-
tion.
14 The fact that the only complication rate reported
which was comparable between the RCT data and most
recent registry population was infection, may reﬂect a
recognition of the need for improved accuracy of the
reporting of this particular most feared complication.
In a recently published Danish registry experience,
15
the total complication rate for any cardiovascular
implantable electronic device (CIED) was reported as
9.5%. This study included all patients on the Danish
Pacemaker and ICD Register undergoing a CIED pro-
cedure from May 2010 to April 2011. Data on complica-
tions were collected, by a physician, through a thorough
and meticulous review and audit of the original data. Of
5918 consecutive patients, 562 experienced at least one
complication. The authors concluded that CIED compli-
cations are more frequent than generally acknowledged.
Measuring outcomes and performance
With a progressive change in attitudes towards the provi-
sion and management of healthcare, physicians must
now formally address the issues of quality measurement,
public reporting and a demand for greater transparency.
Accordingly the ability of sources, such as the NCDR
ICD registry to correctly capture outcomes and perform-
ance is now an important concern and a need for
greater accuracy increasingly recognised. The NCDR is
the world’s largest clinical database of ICD implantation
but is still a relatively young institution; its purpose and
intention continue to evolve. Originally conceived in
2005 in response to a Medicare mandate on primary
prevention ICD implants, it now fulﬁls a number of
roles including acting as a tool for public reporting and
postmarket surveillance. Reporting involves a combin-
ation of incentive payments and payment adjustments,
and is currently voluntary but will become mandatory by
Figure 1 Complication rates in randomised controlled trials
(RCTs) compared to registry.
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Arrhythmias and sudden death2015. Of the participating hospitals, 78% submit data on
all ICD implants, accounting for ∼90% of implant data
entered into the registry. Data quality checks and ran-
domly selected audits are performed, nevertheless as
with any registry, concerns remain about the validity and
accuracy of the data. Improving the data collection
process is essential; physicians should take responsibility
for the quality of data as it will be used to measure per-
formance and quality of care delivery; at the same time,
systems must be designed to minimise the burden of
accurate data collection in order that it does not
become an insurmountably onerous task.
Definition of complications
This review of data from both RCTs and registries high-
lights the poor quality of deﬁnitions and highly variable
reporting of complications across the specialty. It is clear
that there is a need to standardise this practice. Expected
complication rates and a discussion of the risks of ICD
implantation are notably absent in the device guidelines
from both the US
16 17 and European
18 Heart Rhythm
and Cardiac societies, other than in the context of CRT,
19
where the emphasis is predominantly on problems asso-
ciated with the LV lead. The authors propose the devel-
opment and adoption of a universal classiﬁcation system
for the reporting of complications (for all implantable
cardiac devices) allowing meaningful data collection, dis-
tribution, comparison and practice-benchmarking.
Study limitations
There are a number of limitations of this study, mainly
inherent to this type of analysis. As has already been dis-
cussed, a major factor is the variation in reporting of
complications which renders collation of data difﬁcult.
In addition there are several possible confounders of
particular complications which are not known, for
example, the proportion of cephalic versus subclavian
vein access in the studies in which pneumothoraces
occurred, the use of periprocedural antibiotics with
regards to infection rate and the proportion of dual
versus single chamber devices. Finally since this review
focused on implantation only, it did not include details
of arguably one of the most serious ICD adverse events
for the patient’s well-being, namely inappropriate device
therapy or more long-term lead-related complications.
Given the multifactorial nature of these complications,
we believe that this merits a separate analysis.
CONCLUSION
It is clearly evident that implantation of an ICD/pacing
lead carries a signiﬁcant risk of immediate complications
with 1/20 patients suffering an access related events or
early lead displacement. This is a reﬂection of the limita-
tions of current implantation techniques utilising ana-
tomically or ﬂuoroscopy-guided subclavian puncture
(when the cephalic vein is unsuitable) without ultra-
sound guidance. Furthermore, even in the best hands
acute lead stability remains an issue. These factors are
compounded by the longevity of leads and possibility of
multiple replacements particularly in younger patients.
The emergence of subcutaneous ICD and now leadless
pacing systems may mean some of these complications
can be avoided in those not requiring pacing but ven-
tricular deﬁbrillation therapies only.
This systematic review demonstrates a signiﬁcant rate
of complications following ICD implantation and sug-
gests that the incidence observed in RCTs may be higher
than that recorded in registry data. A number of com-
mentators have raised the question of under-reporting
and under-recognition of complications from ICD
implantation in the past.
20–22 Until we establish robust
deﬁnitions and methods of data collection, the opacity
and uncertainty about true risks (and therefore relative
beneﬁts) of device implantation will remain.
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